Nanoparticles in gene-editing therapy may correct CF defects
Researchers have developed nanoparticles that can deliver gene-editing therapeutics to correct genetic defects in the lungs of people with cystic fibrosis (CF). The nanoparticles were optimized using cell-based models to penetrate the thick airway mucus seen in CF. Pretreating patients with the approved mucus-clearing agent Pulmozyme (dornase alfa)…